MACROGENICS INC
About MACROGENICS INC
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $149.5M
- Net income
- -$74.6M
- Total assets
- $256.8M
- Market cap
- $248.5M
- Operating margin
- -48.7%
- Net margin
- -49.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $149.5M
- Cost of revenue
- $0
- Operating expenses
- $222.3M
- Operating income
- -$72.8M
- Income tax
- -$672.0K
- Net income
- -$74.6M
- EPS (basic)
- $-1.18
- EPS (diluted)
- $-1.18
Balance sheet
- Total assets
- $256.8M
- Current assets
- $219.9M
- Total liabilities
- $201.3M
- Current liabilities
- $43.1M
- Shareholders’ equity
- $55.6M
Cash flow
- Operating cash flow
- -$81.0M
- Investing cash flow
- -$114.1M
- Financing cash flow
- $69.5M
- Net cash flow
- -$125.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $248.5M
- EPS (diluted)
- $-1.18
- Shares outstanding
- 64.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 10, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $74.6M in FY2025.
- Revenue grew 93% from FY2021 to FY2025.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MACROGENICS INC.
Write a review
News about MACROGENICS INC
News & sentiment via Polygon.io
